Millennium-led group reports 3.1% stake (41,561 shares)

Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. ownership filing shows a coordinated filing by ICS Opportunities II LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reporting 41,561 shares, representing 3.1% of Common Stock (CUSIP 81728A207) as disclosed on the cover pages. The filing states the holdings reflect shared voting and dispositive power of 41,561 shares among the reporting parties and attaches a Joint Filing Agreement dated 06/02/2026.

The filing clarifies the shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers; the parties note this should not be construed as an admission of beneficial ownership. Signatures are dated 06/02/2026.

Insights

Corporate Governance Analyst

Coordinated 13G/A reports a minority non‑controlling stake of 3.1%.

The filing shows a group filing under a Joint Filing Agreement reporting 41,561 shares and shared voting and dispositive power. This is a passive ownership disclosure consistent with Schedule 13G/A mechanics rather than an active takeover signal.

Future filings may clarify whether the position remains passive; review subsequent schedules for any conversion to a Schedule 13D or changes in voting arrangements.

Institutional Ownership Specialist

Millennium-affiliated entities jointly disclose a small institutional stake in SNSE.

The excerpt lists ICS Opportunities II LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander as filers, each attributing shared dispositive and voting power over 41,561 shares (3.1%). The signature block and Exhibit I indicate a formal joint‑filing arrangement dated 06/02/2026.

Track subsequent Form 13G/A amendments or Form 13D filings for any shift from passive to active intent; cash‑flow treatment is not stated in the excerpt.

Key Figures

Shares reported: 41,561 shares Percent of class: 3.1% CUSIP: 81728A207 +1 more

4 metrics

Shares reported 41,561 shares Amount reported with shared voting/dispositive power

Percent of class 3.1% Percent of common stock reported on cover pages

CUSIP 81728A207 Identifier for Sensei Biotherapeutics common stock

Joint Filing Agreement date 06/02/2026 Exhibit I attached to the Schedule 13G/A

Key Terms

Schedule 13G/A, shared dispositive power, Joint Filing Agreement

3 terms

Schedule 13G/A regulatory

"Item 1. Name of issuer: Sensei Biotherapeutics, Inc."

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

shared dispositive power financial

"Shared Dispositive Power 41,561.00"

Joint Filing Agreement regulatory

"Exhibit I: Joint Filing Agreement, dated as of June 2, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Millennium report in Sensei Biotherapeutics (SNSE)?

The filing reports 41,561 shares, equal to 3.1% of common stock. The disclosure lists shared voting and dispositive power among Millennium entities and related parties and is submitted as a joint Schedule 13G/A.

Who are the filers listed on the Schedule 13G/A for SNSE?

Filers are ICS Opportunities II LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. Their addresses are shown as Millennium Management LLC at 399 Park Avenue, New York.

Does the filing indicate control or beneficial ownership admission?

The filing states the securities are held by entities under Millennium’s voting or investment discretion but notes this should not be construed as an admission of beneficial ownership. A Joint Filing Agreement is attached.

What document formalizes the joint filing for SNSE?

Exhibit I is a Joint Filing Agreement dated 06/02/2026 among the reporting parties. The signatures on the filing are dated 06/02/2026, confirming the coordinated submission.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:52 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Sensei Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

81728A207

(CUSIP Number)

06/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

ICS Opportunities II LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 41,561.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 41,561.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

41,561.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 41,561.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 41,561.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

41,561.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 41,561.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 41,561.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

41,561.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 81728A207

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 41,561.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 41,561.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

41,561.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sensei Biotherapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1405 Research Boulevard, Suite 125, Rockville, Maryland 20850
Item 2.
(a)	Name of person filing: ICS Opportunities II LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: ICS Opportunities II LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: ICS Opportunities II LLC - Cayman Islands Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 81728A207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ICS Opportunities II LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/02/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/02/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/02/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	06/02/2026

Comments accompanying signature: ** ICS OPPORTUNITIES II LLC By: Millennium Management LLC, its Investment Manager

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of June 2, 2026, by and among ICS Opportunities II LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.